A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures

Molecular Neurobiology

Volumn 13, Issue 1, 1996, Pages 33-60

  Post, Robert M ^a   Weiss, Susan R B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Contingent tolerance; Cyclicity; Endogenous adaptations; Gene expression; Manic depressive illness; Recurrence; Time off effect

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTICONVULSIVE AGENT; CARBAMAZEPINE; LITHIUM; VALPROIC ACID;

AFFECT; AMYGDALOID NUCLEUS; ANIMAL; BIPOLAR DISORDER; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; DRUG TOLERANCE; HUMAN; KINDLING; MOOD DISORDER; PATHOPHYSIOLOGY; PERIODICITY; PHYSIOLOGY; RAT; REVIEW; SEIZURE;

AFFECT; AMYGDALA; ANIMALS; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG TOLERANCE; HUMANS; KINDLING, NEUROLOGIC; LITHIUM; MOOD DISORDERS; NEUROTRANSMITTER AGENTS; PERIODICITY; RATS; SEIZURES; VALPROIC ACID;

EID: 0030204096     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02740751     Document Type: Article

References (133)

1. Adamec R. and Stark-Adamec C. (1983) Limbic kindling and animal behavior - Implications for human psychopathology associated with complex partial seizures. Biol. Pscyhiatr. 18, 269-293.
2. Adams J. M. and Cory S. (1991) Transgenic models of tumor development. Science 254, 1161-1166.
3. Ahlfors U. G., Baastrup P. C., Dencker S. J., Eigen K., Lingjaerde O., Pedersen V., Schou M., and Aaskoven O. (1981) Flupenthixol decanoate in recurrent manic depressive illness. A comparison with lithium. Acta Psychiatr. Scand. 64, 226-237.
4. Albertson T. E., Joy R. M., and Stark L. G. (1984) Carbamazepine: a pharmacological study in the kindling model of epilepsy. Neuropharmacology 23, 1117-1123.
5. Arana G. W. and Forbes R. A. (1991) Dexamethasone for the treatment of depression: a preliminary report. J. Clin. Psych. 52, 304-306.
6. Arana G. W., Santos A. B., Laraia M. T., McLeod-Bryant S., Beale M. D., Rames L. J., Roberts J. M., Dias J. K., and Molloy M. (1995) Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am. J. Psych. 152(2), 265-267.
7. Bailey C. H., Chen M., Keller F., and Kandel E. R. (1992) Serotonin-mediated endocytosis of apCAM: an early step of learning-related synaptic growth in aplysia. Science 256, 645-649.
8. Baltzer V., Klebs K., and Schmutz M. (1981) Effects of oxcarbazepine, a compound related to carbamazepine, and of GP 47 779, its main metabolite in man, on the evolution of amygdaloid-kindled seizures in the rat. Presented at Epilepsy International Congress, Kyoto, Japan, September 17-21, 1981.
9. Banki C. M., Bissette G., Arato M., and Nemeroff C. B. (1988) Elevation of immunoreactive CSF TRH in depressed patients. Am. J. Psych. 145, 1526-1531.
10. Banki C. M., Karmacsi L., Bissette G., and Nemeroff C. B. (1992) CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur. J. Neuropsychopharmacol. 2, 107-133.
11. Breier A. (1989) Experimental approaches to human stress research: assessment of neurobiologic mechanisms of stress in volunteers and psychiatric patients. Biol. Psych. 26, 438-462.
12. Brown G. W. and Harris T. O. (1978) Social Origins of Depression. Tavistock, London.
13. Calabrese J. R. and Delucchi G. A. (1989) Phenomenology of rapid cycling manic depression and its treatment with valproate. J. Clin. Psych. 50, 30-34.
14. Calabrese J. R., Woyshville M. J., and Rapport R. T. (1994) Clinical efficacy of valproate, in Anticonvulsants in Mood Disorders (Joffe R. T. and Calabrese J. R., eds.), Marcel Dekker, New York, pp. 131-146.
15. Calabrese J. R., Woyshville M. J., Kimmel S. E., and Rapport D. J. (1993) Predictors of valproate response in bipolar rapid cycling. J. Clin. Psychopharmacol. 13, 280-283.
16. Caldecott-Hazard S. and Engel J. (1987) Limbic postictal events: anatomical substrates and opioid receptor involvement. Prog. Neuropsychopharmacol. Biol. Psychiatr. 11, 389-418.
17. Callahan A., Frye M. A., Marangell L. B., George M. S., Ketter T. A., Kimbrell T. A., L'Herrou T., Pazzaglia P. J., and Post R. M. (1995) Differential mood and endocrine effects of intravenous versus intrathecal TRH. Biol. Psych. 37, 603.
18. Clark M., Massenburg G. S. Weiss S. R. B., and Post R. M. (1994a) Analysis of the hippocampal GABA A receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine. Mol. Brain Res. 26, 309-319.
19. Clark M., Smith M., Weiss S. R. B., and Post R. M. (1994b) Modulation of hippocampal glucocorticoid and mineralocorticoid receptor mRNA expression by amygdaloid kindling. Neuroendocrinology 59, 451-456.
20. Clark M., Post R. M., Weiss S. R. B., Cain C. J., and Nakajima T. (1991) Regional expression of c-fos mRNA in rat brain during the evolution of amygdala-kindled seizures. Mol. Brain Res. 11, 55-64.
21. Dragunow M. (1986) Endogenous anticonvulsant substances. Neurosci. Biobehav. Rev. 10, 229-244.
22. Dubovsky S. L., Franks R. D., Lifschitz M., and Coen P. (1982) Effectiveness of verapamil in the treatment of a manic patient. Am. J. Psych. 139, 502-504.
23. Edelman G. M. (1984) Modulation of cell adhesion during induction, histogenesis, and perinatal development of the nervous system. Ann. Rev. Neurosci. 7, 339-377.
24. Faedda G. L., Tondo L., Baldessarini R. J., Suppes T., and Tohen M. (1993) Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch. Gen. Psych. 50, 448-455.
25. Frank E., Kupfer D. J., Perel J. M., Cornes C., Jarrett D. B., Mallinger A. G., Thase M. E., McEachran A. B., and Grochocinski V. J. (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psych. 47, 1093-1099.
26. Funato T., Yoshida E., Jiao L., Tone T., Kashani-Sabet M., and Scanlon K. J. (1992) The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv. Enzyme Regul. 32, 195-209.
27. Geinisman Y., de Toledo-Morrell L., and Morrell F. (1990) The brain's record of experience: kindling-induced enlargement of the active zone in hippocampal perforated synapses. Brain Res. 513, 175-179.
28. Gelenberg A. J., Kane J. M., Keller M. B, Lavori P., Rosenbaum J. F., Cole K., and Lavelle J. (1989) Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New Engl. J. Med. 321, 1489-1493.
29. Geller B., Fox L. W., and Fletcher M. (1993) Effect of tricyclic antidepressants on switching to mania and on the onset of bipolarity in depressed 6- to 12-year-olds. J. Am. Acad. Child. Adolesc. Psych. 32, 43-50.
30. George M. S., Jones M., Post R. M., Putnam F., Mikalauskas K., and Leverich G. S. (1996) The longitudinal course of affective illness: a mathematical model involving chaos theory. Psych. Res., in press.
31. Gill D. S., Ketter T. A., and Post R. M. (1993) Antidepressant response to sleep deprivation as a function of time into depressive episode in rapidly cycling bipolar patients. Acta Psychiatr. Scand. 87, 102-109.
32. Goddard G. V., McIntyre D. C., and Leech C. K. (1969) A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 25, 295-330.
33. Grof E., Haag M., Grof P., and Haag H. (1987) Lithium response and the sequence of episode polarities: preliminary report on a Hamilton sample. Prog. Neuropsychopharmacol. Biol. Psych. 11, 199-203.
34. Haag H., Heidorn A., Haag M., and Greil W. (1987) Sequence of affective polarity and lithium response: preliminary report on Munich sample. Prog. Neuropsychopharmacol. Biol. Psych. 11, 205-208.
35. Hamra B. J., Nasrallah H. A., Clancy J., and Finn R. (1983) Psychiatric diagnosis and risk for tardive dyskinesia. Arch. Gen. Psych. 40, 346-347.
36. Harnevo L. E. and Agur Z. (1992) Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother. Pharmacol. 30, 469-476.
37. Hennigan R. F., Hawker K. L., and Ozanne B. W. (1994) Fos-transformation activates genes associated with invasion. Oncogene 9, 3591-3600.
38. Hoschl C., Vackova J., and Janda B. (1992) Mood stabilizing effect of verapamil. Bratisl. Lek. Listy. 93, 208-209.
39. Hovorka J., Langmeier M., and Mares P. (1989) Are there morphological changes in presynaptic terminals of kindled rats. Neurosci. Lett. 107, 179-183.
40. Hurowitz G. I. and Liebowitz M. R. (1993) Antidepressant-induced rapid cycling: six case reports. J. Clin. Psychopharmacol. 13, 52-56.
41. Jamison K. R. and Akiskal H. S. (1983) Medication compliance in patients with bipolar disorder. Psychiatr. Clin. North. Am. 6, 175-192.
42. Kalynchuk L. E., Kim C. K., Pinel J. P. J., and Kippin T. E. (1994) Effect of an ascending dose regimen on the development of tolerance to the anticonvulsant effect of diazepam. Behav. Neurosci. 108, 213-216.
43. Kandel E. R. (1993) Genes, synapses and declarative forms of memory. Abstracts of the 146th Annual Meeting of the American Psychiatric Association, 50.
44. Kane J. M. (1988) The role of neuroleptics in manic-depressive illness. J. Clin. Psych. 49, 12-14.
45. Keck Jr. P. E., McElroy S. L., Vuckovic A., and Friedman L. M. (1992) Combined valproate and carbamazepine treatment of bipolar disorder. J. Neuropsych. Clin. Neurosci. 4, 319-322.
46. Keller M. B., Lavori P. W., Kane J. M., Gelenberg A. J., Rosenbaum J. F., Walzer E. A., and Baker L. A. (1992) Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch. Gen. Psych. 49, 371-376.
47. Kessler R. C., McGonagle K. A., Zhao S., Nelson C. B., Hughes M., Eschleman S., Wittchen H., and Kendler K. S. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. Gen. Psych. 51, 8-19.
48. Ketter T. A., Pazzaglia P. T., and Post R. M. (1992) Synergy of carbamazepine and valproic acid in affective illness: Case report and review of literature. J. Clin. Psychopharmacol. 12, 276-281.
49. Ketter T. A., Post R. M., Pazzaglia P. J., Marangell L. B., George M. S., and Callahan, A. (1995) Carbamazepine in the treatment of mania, in Mania (Goodnick P., ed.), American Psychiatric Press, Washington DC, in press.
50. Kraepelin E. (1921) Manic-Depressive Insanity and Paranoia, (Robertson G. M., ed.), Livingstone, Edinburgh.
51. Kramlinger K. G. and Post R. M. (1996) Ultra-rapid and ultradian cycling in bipolar affective illness. Br. J. Psychiatry 168, 314-323.
52. Kukopulos A., Caliari B., Tundo A., Minnai G., Floris G., Reginaldi D., and Tondo L. (1983) Rapid cyclers, temperament, and antidepressants. Compr. Psychiatry 24, 249-258.
53. Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., and Tondo L. (1980) Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatria Neuropsychopharmako. 13, 156-167.
54. Kupfer D. J., Frank E., and Perel J. M. (1989) The advantage of early treatment intervention in recurrent depression. Arch. Gen. Psych. 46, 771-775.
55. Kupfer D. J., Frank E., Perel J. M., Cornes C., Mallinger A. G., Thase M. E., McEachran A. B., and Grochocinski V. J. (1992) Five-year outcome for maintenance therapies in recurrent depression. Arc. Gen. Psych. 49, 769-773.
56. Lafer B., Sachs G. S., Faraone S. V., Thibault A. B., Chaloff J., and Rosenbaum J. F. (1994) High rates of relapse in bipolar patients abruptly changed from standard to low plasma lithium levels in a double-blind, controlled trial. Presented at the First International Conference on Bipolar Disorder, Pittsburgh, PA, June 23-24, 1994, p. 49.
57. Lowe S. W., Ruley H. E., Jacks T., and Housman D. E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
58. Maj M., Pirozzi R., and Kemali D. (1989a) Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology (Berlin) 98, 535-538.
59. Maj M., Pirozzi R., and Starace F. (1989b) Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J. Aff. Disord. 17, 237-241.
60. Maj M., Veltro F., Pirozzi R., Lobrace S., and Magliano L. (1992) Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am. J. Psych. 149, 795-800.
61. Mansouri A., Henle K. J., and Nagle W. A. (1994) Tumor drug-resistance: a challenge to therapists and biologists. Am. J. Med. Sci. 307, 438-444.
62. Marangell L. B., George M. S., Callahan A. M., Ketter T. A., Pazzaglia P. J., L'Herrou T. A., and Post R. M. (1996) Effects of intrathecal thyrotropin-releasing hormone (TRH) in refractory depressed patients. Arch. Gen. Psych., in press.
63. Mayford M., Barzilai A., Keller F., Schacher S., and Kandel E. R. (1992) Modulation of an NCAM-related adhesion molecule with long-term synaptic plasticity in aplysia. Science 256, 638-644.
64. McDermut W., Pazzaglia P. J., Huggins T., Mikalauskas K., Leverich G. S., Ketter T. A., Bartko J., and Post R. M. (1995) Use of single case analyses in off-on-off-on trials in affective illness: a demonstration of the efficacy of nimodipine. Depression 2, 259-271.
65. McElroy S. L., Keck P. E., Pope H. G., and Hudson J. I. (1992) Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J. Clin. Psychopharmacol. 12, 42S-52S.
66. McEwen B. S., Angulo J., Cameron H., Chao H. M., Daniels D., Gannon M. N., Gould E., Mendelson S., Sakai R., and Spencer R. (1992) Paradoxical effects of adrenal steroids on the brain: protection versus degeneration. Biol. Psych. 31, 177-199.
67. McNamara J. O. (1988) Pursuit of the mechanisms of kindling. TINS 11, 33-36.
68. Mellman T. A. and Uhde T. W. (1989) Electroencephalographic sleep in panic disorder. Arch. Gen. Psych. 46, 178-184.
69. Morgan J. I. and Curran T. (1990) Inducible proto-oncogenes of the nervous system: their contribution to transcription factors and neuroplasticity. Prog. Brain Res. 86, 287-294.
70. Muller-Oerlinghausen B., Ahrens B., Volk J., Grof P., Schou M., Vestergaard P., Lenz G., Simhandl C., Thau K., and Wolf R. (1991) Reduced mortality of manic-depressive patients in long-term lithium treatment: an international collaborative study by IGSLI. Psychiatr. Res. 36, 329-331.
71. Muller-Oerlinghausen B., Ahrens B., Grof E., Grof P., Lenz G., Schou M., Simhandl C., Thau K., Volk J., Wolf R., and Wolf T. (1992) The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr. Scan. 86, 218-222.
72. Nemeroff C. B., Widerlov E., and Bissette G. (1984) Elevated concentrations of CSF corticotropin-releasing factor-like irnmunoreactivity in depressed patients. Science 226, 1342-1344.
73. O'Connell R. A., Mayo J. A., Flatow L., Cuthbertson B., and O'Brien B. E. (1991) Outcome of bipolar disorder on long-term treatment with lithium. Br. J. Psych. 159, 123-129.
74. Pazzaglia P. J. and Post R. M. (1992) Contingent tolerance and reresponse to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J. Neuropsychiatr. Clin. Neurosci. 4, 76-81.
75. Pazzaglia P. J., Post R. M., Ketter T. A., George M. S., and Marangell L. B. (1993) Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psych. Res. 49, 257-272.
76. Pinel J. P. J. (1983) Effects of diazepam and diphenylhydantoin on elicited and spontaneous seizures in kindled rats: a double dissociation. Pharmacol. Biochem. Behav. 18, 61-63.
77. Post R. M. (1989) Emerging perspectives on valproate in affective disorders. J. Clin. Psych. 50, 3-9.
78. Post R. M. (1990a) Non-lithium treatment for bipolar disorder. J. Clin. Psych. 51, 9-16.
79. Post R. M. (1990b) Sensitization and kindling perspectives for the course of affective illness: toward a new treatment with the anticonvulsant carbamazepine. Pharmacopsychiatry 23, 3-17.
80. Post R. M. (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psych. 149, 999-1010.
81. Post R. M. and Chuang D.-M. (1991) Mechanism of action of lithium: Comparison and contrast with carbamazepine, in Lithium and the Cell (Birch N. J., ed.), Academic, New York, NY, pp. 199-241.
82. Post R. M. and Weiss S. R. B. (1989) Non-homologous animal models of affective illness: clinical relevance of sensitization and kindling, in Animal Models of Depression (Koob G., Ehlers C., and Kupfer D. J., eds.), Birkhauser Boston, Inc., Boston, MA, pp. 30-54.
83. Post R. M. and Weiss S. R. B. (1992a) Endogenous biochemical abnormalities in affective illness: therapeutic vs. pathogenic. Biol. Psych. 32, 469-484.
84. Post R. M. and Weiss S. R. B. (1992b) Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 25, 41-44.
85. Post R. M. and Weiss S. R. B. (1995) The neurobiology of treatment-resistant mood disorders, in Psychopharmacology: The Fourth Generation of Progress (Bloom F. E. and Kupfer D. J., eds.), Raven, New York, pp. 1155-1170.
86. Post R. M., Altshuler L. L., Ketter T. A., Denicoff K., and Weiss S. R. B. (1991) Antiepileptic drugs in affective illness: Clinical and theoretical implications, in Advances in Neurology, vol 55: Neurobehavioral Problems in Epilepsy (Smith D. B., Treiman D. M., and Trimble M. R., eds.), Raven, New York, pp. 239-277.
87. Post R. M., Ketter T. A., Pazzaglia P. J., Denicoff K., George M. S., Callahan A., Leverich G., and Frye M. (1996) Rational polypharmacy in the bipolar affective disorders. Epilepsia Res., in press.
88. Post R. M., Leverich G. S., Altshuler L., and Mikalauskas K. (1992a) Lithium discontinuation-induced refractoriness: preliminary observations. Am. J. Psych. 149, 1727-1729.
89. Post R. M., Weiss S. R. B., and Chuang D.-M. (1992b) Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J. Clin. Psychopharmacol. 12, 23S-35S.
90. Post R. M., Leverich G. S., Pazzaglia P. J., Mikalauskas K., and Denicoff K. (1993) Lithium tolerance and discontinuation as pathways to refractoriness, in Lithium in Medicine and Biology (Birch N. J., Padgham C., and Hughes M. S., eds.), Marius, Lancashire, UK, pp. 71-84.
91. Post R. M., Leverich G. S., Rosoff A. S., and Altshuler L. L. (1990a) Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J. Clin. Psychopharmacol. 10, 318-327.
92. Post R. M., Weiss S. R. B., Clark M., Nakajima T., and Pert A. (1990b) Amygdala versus local anesthetic kindling: differential anatomy, pharmacology, and clinical implications, in Kindling IV (Wada J., ed.), Plenum, New York, pp. 357-369.
93. Post R. M., Putnam F., Uhde T. W., and Weiss S. R. B. (1986a) ECT as an anticonvulsant: implications for its mechanism of action in affective illness, in Electroconvulsive Therapy: Clinical and Basic Research Issues, Ann NY Acad Sci, vol. 462 (Malitz S. and Sackheim H. A., eds.), New York Academy of Sciences, New York, NY, pp. 376-388.
94. Post R. M., Rubinow D. R., and Ballenger J. C. (1986b) Conditioning and sensitization in the longitudinal course of affective illness. Br. J. Psych. 149, 191-201.
95. Post R. M., Putnam F. W., Contel N. R., and Goldman B. (1984a) Electroconvulsive seizures inhibit amygdala kindling: implications for mechanisms of action in affective illness. Epilepsy 25, 234-239.
96. Post R. M., Rubinow D. R., and Ballenger J. C. (1984b) Conditioning, sensitization, and kindling: implications for the course of affective illness, in Neurobiology of Mood Disorders Post R. M. and Ballenger J. C., eds.), Williams & Wilkins, Baltimore, MD, pp. 432-466.
97. Post R. M., Weiss S. R. B., Chuang D., and Ketter T. A. (1994) Mechanisms of action of carbamazepine in seizure and affective disorders, in Anticonvulsants in Mood Disorders (Joffe R. T. and Calabrese J. R., eds.), Marcel Dekker, New York, pp. 43-92.
98. Racine R. (1978) Kindling: the first decade. Neurosurgery 3, 234-252.
99. Rocamora N., Placios J. M., and Mengod G. (1992) Limbic seizures induce a differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor and neurotropin-3, in the rat hippocampus. Mol. Brain Res. 13, 27-33.
100. Rosen J. B., Abramowitz J., and Post R. M. (1993) Co-localization of TRH mRNA and Fos-like immunoreactivity in limbic structures following amygdala kindling. Mol. Cell Neurosci. 4, 335-342.
101. Rosen J. B., Cain C. J., Weiss S. R. B., and Post R. M. (1992) Alterations in mRNA of enkephalin, dynorphin and thyrotropin releasing hormone during amygdala kindling: an in situ hybridization study. Mol. Brain Res. 15, 247-255.
102. Rosen J. B., Weiss S. R., and Post R. M. (1994) Contingent tolerance to carbamazepine: alterations in TRH mRNA and TRH receptor binding in limbic structures. Br. Res. 651, 252-260.
103. Rouillon F., Phillips R., Serrurier D., Ansart E., and Gerard M. J. (1989) Recurrence of unipolar depression and efficacy of maprotiline. Encephale 15, 527-534.
104. Rouillon F., Serrurier D., Miller H. D., and Gerard, M. J. (1991) Prophylactic efficacy of maprotiline on unipolar depression relapse. J. Clin. Psych. 52, 423-431.
105. Sachs G. S., Lafer B., Truman C. J., Noeth M., and Thibault A. B. (1994) Lithium monotherapy: miracle, myth and misunderstanding. Psychiatr. Ann. 24, 299-306.
106. Sackheim H. A. (1988) Mechanisms of action of electroconvulsive therapy, in Annual Review of Psychiatry, vol 7 (Hales R. E., Frances J., eds.), American Psychiatric, Washington DC, pp. 438-457.
107. Schmutz M., David J., Grewal R. S., Bernasconi R., and Baltzer V. (1986) Pharmacological and neurochemical aspects of tolerance, in Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs (Koella W. P., ed.), Raven, New York, pp. 25-36.
108. Schou M. (1979) Lithium as a prophylactic agent in unipolar affective illness. Arch. Gen. Psych. 36, 849-851.
109. Smith M. A., Makino S., Kvetnansky R., and Post R. M. (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 15(3), 1768-1777.
110. Spiller A. E. and Racine R. J. (1994) Transfer kindling between sites in the entorhinal cortex-perforant path-dentate gyrus system. Brain Res. 28, 130-138.
111. Suppes T., Baldessarini R. J., Faedda G. I., and Tohen M. (1991) Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psychiatr. 48, 1082-1088.
112. Sutula T., Cavazos J., and Golarai G. (1992a) Alteration of long-lasting structural and functional effects of kainic acid in the hippocampus by brief treatment with phenobarbital. J. Neurosci. 12, 4173-4187.
113. Sutula T. P., Golarai G., and Cavazos J. (1992b) Assessing the functional significance of mossy fiber sprouting. Epilep. Res. Suppl. 7, 251-259.
114. Sutula T. P. (1991) Reactive changes in epilepsy: cell death and axon sprouting induced by kindling. Epilep. Res. 10, 62-70.
115. Tuff L. P., Racine R. J., and Mishra R. K. (1983) The effects of kindling on GABA-mediated inhibition in the dentate gyrus of the rat. II. Receptor binding. Brain Res. 277, 91-98.
116. Wada J. A. (1977) Pharmacological prophylaxis in the kindling model of epilepsy. Arch. Neurol. 34, 389-395.
117. Waddington J. L., Brown K., O'Neill J., McKeon P., and Kinsella, A. (1989) Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder: relationship to tardive dyskinesia. Psychol. Med. 19, 897-902.
118. Wallace C. S., Hawrylak N., and Greenough W. T. (1991) Studies of synaptic structural modifications after long-term potentiation and kindling: context for a molecular morphology, in Long-Term Potentiation: A Debate of Current Issues (Baudry M. and Davis J. L., eds.), MIT, Cambridge, MA, pp. 189-232.
119. Wehr T. A. (1993) Can antidepressants induce rapid cycling? Arch. Gen. Psych. 50, 495-496.
120. Wehr T. A. and Goodwin F. K. (1979) Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch. Gen. Psych. 36, 555-559.
121. Wehr T. A., Sack D. A., Rosenthal N. E., and Cowdry R. W. (1988) Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am. J. Psych. 145, 179-184.
122. Weissman M. M., Leaf P. J., Tischler G. L., Blazer D. G., Karno M., Bruce M. L., Florio L. P., and Livingston-Bruce M. (1988) Affective disorders in five United States communities. Psychol. Med. 18, 141-153.
123. Weiss S. R. B. and Post R. M. (1987) Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala kindled seizures in the rat but do not block their development. Clin. Neuropharmacol. 10, 272-279.
124. Weiss S. R. B. and Post R. M. (1990) Contingent tolerance to the anticonvulsant effects of carbamazepine: implications for neurology and psychiatry, in Carbamazepine: A Bridge Between Epilepsy and Psychiatric Disorders (Canger R., Sacchetti E., Perini G. I., and Canevini M. P., eds.), Origgio: Ciba-Geigy Edizioni, Origgio, pp. 7-32.
125. Weiss S. R. B. and Post R. M. (1995) Caveats in the use of the kindling model of affective disorders. J. Toxicol. Indust. Hlth. 10, 421-447.
126. Weiss S. R. B., Clark M., Rosen J. B., Smith M. A., and Post R. M. (1995) Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res. Rev. 20, 305-325.
127. Weiss S. R. B., Haas K., and Post R. M. (1991) Contingent tolerance to carbamazepine is associated with lowering of amygdala-kindled seizure thresholds. Exp. Neurol. 114, 300-306.
128. Weiss S. R. B., Heynen T., Noguera C. C., Li X., and Post R. M. (1994) Oscillating patterns of anticonvulsant responsivity: putative model of affective illness cyclicity. ACNP Abst. 210.
129. Weiss S. R. B., Post R. M., Sohn E., Berger A., and Lewis R. (1993) Cross tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilep. Res. 16, 37-44.
130. Winokur G., Coryell W., Keller M., Endicott J., and Akiskal H. (1993) A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Arch. Gen. Psych. 50, 457-465.
131. Yassa R., Ghadirian A. M., and Schwartz G. (1983) Prevalence of tardive dyskinesia in affective disorder patients. J. Clin. Psych. 44, 410-412.
132. Yassa R., Nair N. P. V., Iskandar H., and Schwartz G. (1990) Factors in the development of severe forms of tardive dyskinesia. Am. J. Psych. 147, 1156-1162.
133. Zola-Morgan S. (1994) How memory is organized in the brain. ACNP Abst. 33.